Evidence map›Paper›PMID 37775523›Full record

ArticleBritish journal of cancer2023

Vitamin C intake and colorectal cancer survival according to KRAS and BRAF mutation: a prospective study in two US cohorts.

Shanshan Shi, Kai Wang, Tomotaka Ugai, Marios Giannakis, Jules Cazaubiel, Andrew T Chan, Edward L Giovannucci, Jonathan A Nowak, Jeffrey A Meyerhardt, Shuji Ogino and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Shanshan ShiDepartment of Pathology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Kai WangDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.ORCID 0000-0002-5614-5618
Tomotaka UgaiDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Marios GiannakisBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Jules CazaubielDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Andrew T ChanBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0001-7284-6767
Edward L GiovannucciDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.ORCID 0000-0002-6123-0219
Jonathan A NowakProgram in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
Jeffrey A MeyerhardtDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-1120-0898
Shuji Ogino *Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.ORCID 0000-0002-3909-2323
Mingyang Song *Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. mis911@mail.harvard.edu.ORCID 0000-0002-1324-0316
Harvard University · USBroad Institute · USBrigham and Women's Hospital · US

Funding

Coffee and metabolites modulating the gut microbiome for improved colorectal cancer survivalR01CA263776 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Mingyang Song · 2022 to 2026
$3.3M
The Gut Microbiome, Lifestyle, and Colorectal NeoplasiaU01CA261961 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Mingyang Song · 2022 to 2026
$3.0M
Dietary prevention for colorectal cancer: targeting the bile acid/gut microbiome axisK99CA283146 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI WANG, KAI · 2023 to 2024
$244k
Cancer Research UK 27140NCI NIH HHS K99 CA283146NCI NIH HHS R01 CA263776NCI NIH HHS U01 CA261961
6 · The paper itself

Abstract

backgroundThe associations of vitamin C intake with colorectal cancer (CRC) survival according to tumour KRAS or BRAF mutation status remain unclear.

methodsWe used the inverse probability weighted multivariable Cox proportional hazards regression model to calculate the hazard ratio (HR) of mortality, and spline analysis to evaluate the dose-response relationship in the Nurses' Health Study and Health Professionals Follow-up Study. We also assessed SLC2A1 mRNA expression according to KRAS or BRAF mutation in the TCGA database.

resultsDuring an average of 12.0 years of follow-up, we documented 2,096 CRC cases, of which 703 cases had KRAS and BRAF mutation data. The association between total vitamin C intake and CRC-specific mortality suggestively differed according to KRAS or BRAF mutation status (P

conclusionOur findings support the laboratory evidence for a potential benefit of vitamin C for CRC patients with KRAS or BRAF mutated tumours.

Indexed as

Colorectal NeoplasmsProto-Oncogene Proteins B-rafFollow-Up StudiesHumansMutationProspective StudiesProto-Oncogene Proteins p21(ras)RNA, MessengerBRAF protein, humanKRAS protein, humanProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)RNA, Messenger

Identifiers

PMID37775523
PMCPMC10667518
OpenAlexW4387209985

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.